Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (88) clinical trials

Study of Taladegib in Combination With Weekly Paclitaxel Carboplatin and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group (Phase 1B or Phase 2) based on when you join this study. If you are in Phase 1B, the dose of Taladegib that you will receive is ...

Phase

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction

Patients will be enrolled in two cohorts. The cohorts 1 an d2 will be conducted consecutively, started with cohort 1. Cohort 1 consists of 30 patients who receive S-1 twice daily for 18 cycles (D1-14 q 3 wks). Cohort 2 consists of 30 patients who receive S-1 twice daily for ...

Phase

A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

Phase

Study of 5-fluorouracil (5-FU) Nab 1-paclitaxel Bevacizumab Leucovorin and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

The Phase 1 portion of the study is an open-label study enrolling subjects with metastatic pancreatic adenocarcinoma who have not previously received systemic chemotherapy at any time as treatment for pancreatic cancer (including adjuvant chemotherapy), except low dose chemotherapy administered as a radiosensitizer concomitant with radiotherapy and to determine the ...

Phase

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

This is a first-in-human, two-part, open-label, safety, pharmacokinetic, and efficacy study of oral CK-101 administered daily in ascending doses in patients with advanced solid tumor cancer, followed by a Phase 2 portion at the recommended Phase 2 dose (RP2D) in previously treated non-small cell lung cancer (NSCLC) patients who have ...

Phase

Durvalumab an Anti-PD-L1 Antibody and Chemoradiation Before Surgery for Esophageal Cancer

The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation using two standard chemotherapy drugs, carboplatin and paclitaxel. The investigators want to find out what effects, good and/or bad, this combination has on the patient and cancer.

Phase

G1T38 a CDK 4/6 Inhibitor in Combination With Fulvestrant in Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer

This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study is an open-label design, consists of 2 parts: dose-finding portion (Part 1), and expansion portion (Part 2). Both parts ...

Phase

LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

This is a single arm, open label Phase I/II study to evaluate the progression free survival at 8 weeks (PFS8week) of the combination of LEE-011 plus everolimus, in patients with metastatic pancreatic cancer refractory to 5-fluorouracil (5-FU) and gemcitabine-based chemotherapy. Previous studies of third-line therapy in mPAC are limited but ...

Phase

Phase 1/2A Study of TRC253 an Androgen Receptor Antagonist in Metastatic Castration-resistant Prostate Cancer Patients

The patient population consists of men 18 years of age with adenocarcinoma of the prostate with metastatic disease. Patients who have not undergone orchiectomy must have serum testosterone levels <50 ng/dL determined within 4 weeks prior to start of study drug, and, if applicable, must have discontinued treatment with first ...

Phase

MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to 1 of 4 dose levels based on when you join this study. The dose of MGCD516 you receive will depend on how well previously enrolled patients tolerated the study drug. ...

Phase